E

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017
E
Berlin Wall Museum

Can we use immunotherapy to treat or delay Alzheimers Disease?

How we could use our immune system against Alzheimer's?

July 20, 2017
E

Can epigenetic therapy boost cancer immunotherapy?

A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?

July 19, 2017
E

When targeted and immunotherapy worlds collide

A look at an up and coming small cap biotech developing targeted and immunotherapy agents for the treatment of cancer.

July 6, 2017
E

Why did Atezolizumab fail in advanced Urothelial Bladder Cancer?

Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.

June 27, 2017
E

Gems from the ASCO17 Poster Hall Part 1

A look at how liver mets can negatively impact cancer immunotherapies

June 22, 2017
E

Can a vaccine make a difference in sarcoma?

What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?

June 21, 2017
E

New developments in sarcoma

What's new in the sarcoma space? Which novel approaches are worth watching out for?

June 20, 2017
E

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017
E

New IO developments in breast cancer

A look at checkpoint blockade in early stage breast cancer - encouraging or not?

June 14, 2017
E

Going beyond PARP monotherapies

A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO

June 13, 2017
E

An in-depth look at OLYMPIAD in HER2 negative breast cancer

Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?

June 12, 2017
E

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017
E

Is 2017 the Year of the Cancer Vaccine?

A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.

February 21, 2017
E

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017
E

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017
E

Do Exosomes Matter?

With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.

May 2, 2017
E

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017
E

Can Jonathan Lim ignite the TRK oncology space?

An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition

April 26, 2017
E

Can AZN take immuno-oncology to the next level?

Through the keyhole with a look at AZN and MedImmune's IO portfolio

April 25, 2017
E

What do we know about Resistance to Checkpoints in Lung Cancer?

Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts

April 20, 2017
E

Potential of CAR T cell therapy targeting Glioblastoma

Encouraging new developments in GBM with a novel CAR T cell therapy

April 18, 2017
E

Overcoming Cancer Immunotherapy Resistance

How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.

April 17, 2017
E

Dan Chen outlines his vision for the Future of Cancer Immunotherapy at AACR17

Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.

April 13, 2017
E

What does atezolizumab TNBC data presented at AACR17 tell us about breast cancer immunotherapy?

Interview with Professor Peter Schmid, Barts Cancer Institute.

April 10, 2017
E
Ira Mellman Dan Chen Authors of Cancer Immunity Cycle

Understanding the Cancer-Immune Set Point

A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.

February 22, 2017
E

Blueprint Shows Promise in GIST and HCC

Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...

February 16, 2017
E

A completely novel approach to targeting hematologic malignancies

A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.

February 15, 2017
E

Novel Targets in Multiple Myeloma

Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?

February 8, 2017
E

Targeting the tumour environment in Lymphomas

What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.

February 6, 2017
E

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017
E

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017
E

Is Tucatinib better than Neratinib in HER2-positive Breast Cancer?

2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...

January 30, 2017
E

Understanding the Mutational Landscape of Metastatic Breast Cancer

How crowdsourcing data from breast cancer patients may help future clinical R&D

January 24, 2017
E

Targeting Breast Cancer Stem Cells

Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?

January 23, 2017
E

Challenges and Opportunities in Inflammatory Breast Cancer

SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.

January 17, 2017
E

How circulating tumor DNA could change cancer treatment

SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.

January 16, 2017
E
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017
E

Still looking for a JPM17 Licensing Deal? How about a First-in-Class Drug for Metastatic Breast Cancer?

First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.

January 12, 2017
E

The future of CAR T cells in pediatric ALL

Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL

January 9, 2017
E

Promising new agents to watch out for in Chronic Lymphocytic Leukemia

A look at some promising agents in new product development emerging in early CLL trials

January 6, 2017
E

The Changing CLL Landscape Part 1

How are recently approved novel therapies impacting the CLL landscape and where are we going next?

January 5, 2017
E

Does Polatuzumab Vedotin have Potential in Lymphomas?

A look at the latest data for a CD79b targeted ADC in lymphomas

January 4, 2017
E

How the Leukemia Lymphoma Society plans to Beat AML

Tackling heterogeneity in older people with AML using novel targeted therapies.

December 21, 2016
E

LeonardList showcases 10 Lymphoma Abstracts at ASH16

#LeonardList showcases 10 Lymphoma Abstracts at ASH16

December 19, 2016
E

SITC 2016 Can Nektar Boost Checkpoint Performance

Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...

November 16, 2016
E

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016
E

Insights from biomarkers in ovarian cancer

Can biomarkers help us improve clinical trial outcomes?

October 25, 2016
E

Where does rucaparib fit in ovarian cancer?

How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?

October 24, 2016
E

What do Myriad Genetics really think of the Niraparib data?

Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented

October 20, 2016
E

New Directions in Advanced Lung Cancer

Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…

October 19, 2016
E

What Tesaro aren’t telling you about niraparib

What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.

October 8, 2016
E

How do you calculate Immunoscore? A tour of HalioDx

Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay

October 3, 2016
E
Dr Eric Pamer presenting at CIML40

Manipulating the Microbiota to Improve Clinical Outcomes. An interview with Eric Pamer

Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.

September 28, 2016
E

Targeting Natural Killer Cells in AML

New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.

September 27, 2016
E

Corvus moves fast to target tumor microenvironment and improve checkpoint responses

Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.

September 26, 2016
E
Professor Ton Schumacher at CIML40

Is Targeting Neoantigens the Next Frontier in Cancer Immunotherapy?

Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).

September 22, 2016
E

François Romagné Accelerates Cancer Immunotherapy Innovation in Marseille

Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.

September 21, 2016
E

Innate Pharma at an Inflexion Point. An interview with CEO Hervé Brailly

Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company

September 20, 2016
E

Why target the Innate Immune system? An interview with Eric Vivier

Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.

September 19, 2016
E

HalioDX CEO Vincent Fert outlines commercial strategy for Immunoscore in US and Europe

Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.

September 14, 2016
E

Modelling the Tumour Microenvironment

Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer

August 22, 2016
E

PsiOxus is a cancer immunotherapy company to watch – Part 2 of an interview with CEO John Beadle

Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.

August 17, 2016
E

Can PsiOxus become a world leading immuno-oncolytic virus company?

An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours

August 16, 2016
E

NEON shines the light on Neoantigen targeted Cancer Immunotherapy

Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...

August 11, 2016
E

Can neoantigen vaccines make a difference in cancer research?

This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.

August 10, 2016
E

How to turn a cold tumour into a hot one

Can we turn a cold tumour into a hot one where some patients can respond to therapy?

June 23, 2016
E

Immunoscore validated as an important biomarker for colon cancer

An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.

June 20, 2016
E

Contemplations on ASCO Lung Cancer Data with Dr Stephen Liu

What to make of the various combination trials presented at ASCO 2016?

June 13, 2016
E

What we learnt at AACR about Aduro ADU-S100

Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...

May 25, 2016
E

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016
E

Is APRIL an exciting new target in Multiple Myeloma?

A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target

May 11, 2016
E

Targeting OX40 in advanced cancers – Part 2

Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.

May 10, 2016
E

AACR Cancer Immunotherapy Insights from Dr Bernard Fox

A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!

May 9, 2016
E

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016
E

Controversy: Is Chemotherapy Immunotherapy?

Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...

May 3, 2016
E

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016
E

Are checkpoints playing with fire?

Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”

February 25, 2016
E

Optimizing CD19 CAR T Cell Therapy

Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy

February 23, 2016
E

Challenges and Opportunities of CAR T Cell Therapy in CLL

Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL

February 19, 2016
E

The Next Big Wave in Multiple Myeloma

How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?

February 11, 2016
E

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016
E

Immunotherapy for Lymphoma using T cells Targeting Multiple Tumor-Associated Antigens

A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.

February 3, 2016
E

Is Ocular Toxicity a big deal with Denintuzumab Mafodotin SGN-CD19A? #JPM16

An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.

January 11, 2016
E

Midostaurin in AML – Better Late than Never!

An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.

January 6, 2016
E

New Horizons in CLL Treatment

ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.

January 5, 2016
E
ASH15 Late Breaker Session

New Treatments for CLL with Deletions in 17p

A look at the new CLL 17p deletion data at ASH in the late breaker session

January 4, 2016
E

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015
E

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015
E

Exploring the Potential of Therapeutic Cancer Vaccines

At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.

November 23, 2015
E

Novel Immunotherapies and Combinations

Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations

November 17, 2015
E

Gut Bacteria Impact Checkpoint Inhibitor efficacy

Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.

November 16, 2015
E

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015
E

How long do we need to give a checkpoint inhibitor for?

At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...

November 11, 2015
E

Do Cellectis CAR T Cells Really Work?

Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL

November 10, 2015
E

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015
E

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015
E

Is ocrelizumab a game changer in MS?

At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.

October 11, 2015
E

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015
E

Potential of Checkpoint Inhibitors in Ovarian Cancer

Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types

October 5, 2015
E
Dr Holbrook Kohrt

Holbrook Kohrt leads the way in Targeting CD137

Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).

September 15, 2015
E

Immunocore ImmTAC TCR platform offers combination promise

Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.

September 14, 2015
E

Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment

Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer

September 3, 2015
E

Adoptive Cell Therapies – an interview with Dr Carl June

Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours

August 14, 2015
E

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015
E
Dr William Pao Roche

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.

July 1, 2015
E

Future of Prostate Cancer Immunotherapy

ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.

June 29, 2015
E

Tom Gajewski takes the STING out of Cancer

Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.

May 13, 2015
E

Impact of TERRAIN trial on European Prostate Cancer treatment landscape #EAU15

The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.

March 24, 2015
E

Cellular therapy with EBV-CTL reduces death post stem cell transplant

What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?

March 20, 2015
E

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015
E
View of Cambridge and Charles River

Yumanity hopes to impact humanity – an interview with Dr Susan Lindquist

Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.

January 21, 2015
E

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015
E

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015
E

Bellicum moves BPX-501 T Cell Therapy forward $BLCM

What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.

January 13, 2015
E

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015
E

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015
E

Can you reduce Graft versus Host Disease GvHD by regulating gut bacteria?

At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.

November 18, 2014
E
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
E

ASCO 2014 Diffuse Large B Cell Lymphoma DLBCL Progress

Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.

June 30, 2014
E

Making a difference in advanced bladder cancer

There have been no new therapies in urothelial bladder cancer for 30 years - until now...

June 17, 2014
E

Super Enhancers – what are they and why do they matter in cancer research?

Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.

April 14, 2014
E

ASCO GU 2014: Will there be a market for Medivation’s enzalutamide in M0 prostate cancer?

The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?

February 10, 2014
E

ASCO GU Interview with Dr Tom Beer on Medivation PREVAIL trial data

Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial

January 28, 2014
E

Can Agios score a winner with their anti-cancer metabolism molecules?

Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma. Will they be successful despite the huge complexity involved in the underlying processes?

January 13, 2014
E

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013
E

FDA Breakthrough Therapy Designation Benefits – part 2 of an interview with John Jenkins

FDA Office of New Drugs Director John Jenkins discusses the benefits of the Breakthrough Therapy designation and some of the challenges the agency faces in administering it.

November 26, 2013
E

Understanding the Breakthrough Therapy Designation – Part 1 of an interview with FDA New Drugs Director John Jenkins

John K. Jenkins, MD, Director of the Office of New Drugs, Center for Drug Evaluation and Research at the FDA offers a senior management perspective on what is a breakthrough?

November 15, 2013
E

Dr Oliver Sartor shares his thoughts on Prostate Cancer data at ECCO 2013

Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.

September 30, 2013
E
Dr Deepak Sampath, Genentech

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).

November 1, 2013
E

ASCO 2013 Video Interview with Dr Susan O’Brien on CLL new drugs in development

It's exciting times in Chronic Lymphocytic Leukemia (CLL) with a lot of new data expected at the forthcoming 2013 annual meeting of the American Society of Hematology (#ASH13) in New Orleans. At ASCO 2013, Dr Susan O'Brien shared her thoughts on several new CLL drugs in development including ABT-199, ibrutinib, idelalisib, AV-292, obinutuzumab and IP-145.

June 10, 2013